Results 101 to 110 of about 19,369 (169)

Positively Charged Polymers Based on Cyclodextrins for Trametinib and Selumetinib Delivery in Glioblastoma Cancer. [PDF]

ChemMedChem
Bognanni N, Gentile MT, Feola A, Giglio V, Dragone M, Isernia C, Vecchio G.   +6 more
europepmc   +1 more source

Growth factors maintain intratumoral heterogeneity and drive therapeutic resistance in triple-negative breast cancer. [PDF]

Cell Rep
Devlin KL, Smith R, Bucher E, Dane M, Bowman CL, Carlson EJ, Kilburn D, Sudar D, Feiler HS, Heiser LM, Langer EM, Korkola JE.   +11 more
europepmc   +1 more source

Trametinib Decreased Intracerebral Hemorrhages and Endothelial-to-Mesenchymal Transition in KRAS^G12V-Induced Brain Arteriovenous Malformations in Mice. [PDF]

Stroke
Myint O, Freeman BH, Jeong J, Park H, Wilfur SM, Huang S, Park JE, Körbelin J, Aronowski J, Park ES, Chen PR, Kim E.   +11 more
europepmc   +1 more source

Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. [PDF]

PLoS One
Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ.   +19 more
europepmc   +1 more source

Proximity-Based Phospho-Interactome (Prob-PhI) Characterization Reveals Distinct Signaling Activities of MEK1 and MEK2. [PDF]

Anal Chem
Wang Y, Xiao P, Fan L, Pan Y, Ma H, Wang R, Xu C, Zhang L.   +7 more
europepmc   +1 more source

Ribosome biogenesis as a potential therapeutic target in KRAS mutant colorectal cancer. [PDF]

Nat Commun
Tanaka Y, Sakahara M, Yamanaka H, Natsume Y, Kusama D, Kumegawa K, Yoshikawa H, Abe Y, Okabayashi K, Matui S, Kitagawa Y, Koshikawa N, Osumi H, Shinozaki E, Nagayama S, Adachi J, Maruyama R, Yao R.   +17 more
europepmc   +1 more source

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series. [PDF]

Front Endocrinol (Lausanne)
Yamin T, Cohen O, Robenshtok E, Izkhakov E, Miodovnik M, Gutfeld O, Leshem Y, Meirovitz R, Warshavsky A, Muhanna N, Finkel I.   +10 more
europepmc   +1 more source

Fatal tracheal perforation following Dabrafenib-Trametinib therapy in <i>BRAF</i> V600E-mutant mixed anaplastic thyroid cancer. [PDF]

JCEM Case Rep
Matrone A, Scordo M, Minaldi E, Torregrossa L, Materazzi G, Elisei R.   +5 more
europepmc   +1 more source

Intratumoral delivery of probiotic Ligilactobacillus salivarius H22A013 modulates the melanoma microenvironment and enhances trametinib efficacy. [PDF]

BMC Microbiol
Zhen D, Han Z, Yang Z, Tu H, Liu X, Zhang J, Huo D.   +6 more
europepmc   +1 more source

Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i>^<i>V600E</i> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H. [PDF]

JCO Precis Oncol
Salama AKS, Wang V, Macrae ER, Park JI, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.   +18 more
europepmc   +1 more source